Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

HARP
Harpoon Therapeutics Inc
stock NASDAQ

At Close
1/27/2023 3:59:52 PM EST
1.18USD+25.532%(+0.24)2,238,936
1.14Bid   1.21Ask   0.07Spread IEX
Pre-market
1/27/2023 9:27:30 AM EST
0.9699USD+3.181%(+0.0299)0
After-hours
1/27/2023 4:02:30 PM EST
1.13USD-3.830%(-0.05)0
OverviewOption ChainHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsMore
open chart   
open chart   
Market Cap
39.066M
Headquarters
South San Francisco, California, USA
Industry
Biotechnology
HARP Stats
Avg. Vol. 10 Day
418,676
Avg. Vol. 30 Day
540,837
Employees
86
Market Cap
39,065,986
Shares Out.
33,106,768
On/Off Exchange
44%/56%
6 Month Beta
1.62
1 Year Beta
1.65
2 Year Beta
1.45
3 Year Beta
1.20
52 Week Low
0.59
52 Week High
6.20
SMA50
0.80
SMA200
1.27
1 Week
+36.70%
1 Month
+97.66%
3 Month
+25.64%
6 Month
-42.72%
1 Year
-76.54%
2 Year
-93.68%
5 Year
-91.26%
Jan 11, 2022
08:14AM EST  Harpoon Therapeutics Provides Pipeline Development Milestones For 2022   Benzinga
08:00AM EST  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeline milestone update on its TriTAC development programs.   GlobeNewswire Inc
Dec 13, 2021
04:11PM EST  Harpoon Therapeutics Offers Pipeline Update For TriTAC Programs, T Cell Engager Platforms   Benzinga
04:05PM EST  Harpoon Therapeutics Provides Pipeline Update for   GlobeNewswire Inc
Dec 11, 2021
09:11AM EST  Harpoon Therapeutics Presented Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC HPN217 at ASH 2021; Said Encouraging Clinical Activity in Higher Dose cohorts with 63% ORR and 88% DCR Reported in 2150 g/week Cohort with 8 Disease Evaluable Patients with Relapsed/refractory Multiple Myeloma   Benzinga
More News
Profile
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient's own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor.

HARP Stock Summary

Harpoon Therapeutics Inc (NASDAQ:HARP) stock price today is $1.18, and today's volume is 2,238,936. HARP is up 25.532% today. The 30 day average volume is 540,837. HARP market cap is 39.066M with 33,106,768 shares outstanding.



Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC